الگو:دمای بدن انسان

منابع

↑ Marx, John (2006). Rosen's emergency medicine: concepts and clinical practice. Mosby/Elsevier. p. 2239. ISBN 978-0-323-02845-5.
↑ Hutchison, James S.; et al. (June 2008). "Hypothermia therapy after traumatic brain injury in children". New England Journal of Medicine. 358 (23): 2447–2456. doi:10.1056/NEJMoa0706930. PMID 18525042.
↑ Pryor, Jennifer A.; Prasad, Ammani S. (2008). Physiotherapy for Respiratory and Cardiac Problems: Adults and Paediatrics (به انگلیسی). Elsevier Health Sciences. p. 8. ISBN 0-7020-3974-8.
↑ ^۴٫۰ ^۴٫۱ Axelrod, Yekaterina K.; Diringer, Michael N. (May 2008). "Temperature management in acute neurologic disorders". Neurologic Clinics. 26 (2): 585–603, xi. doi:10.1016/j.ncl.2008.02.005. PMID 18514828.
↑ ^۵٫۰ ^۵٫۱ Laupland, Kevin B. (July 2009). "Fever in the critically ill medical patient". Critical Care Medicine. 37 (7 Suppl): S273–8. doi:10.1097/CCM.0b013e3181aa6117. PMID 19535958.
↑ Grunau, Brian E.; Wiens, Matthew O.; Brubacher, Jeffrey R. (September 2010). "Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review". Canadian Journal of Emergency Medicine. 12 (5): 435–442. doi:10.1017/s1481803500012598. PMID 20880437. Dantrolene may also be associated with improved survival and reduced complications, especially in patients with extreme (≥ 42 °C) or severe (≥ 40 °C) hyperpyrexia
↑ Sharma, Hari Shanker, ed. (2007). Neurobiology of Hyperthermia (1st ed.). Elsevier. pp. 175–177, 485. ISBN 978-0-08-054999-6. Retrieved 19 November 2016. Despite the myriad of complications associated with heat illness, an elevation of core temperature above 41.0 °C (often referred to as fever or hyperpyrexia) is the most widely recognized symptom of this syndrome.

[Rosen-1] Marx, John (2006). Rosen's emergency medicine: concepts and clinical practice. Mosby/Elsevier. p. 2239. ISBN 978-0-323-02845-5.

[pmid18788094-2] Hutchison, James S.; et al. (June 2008). "Hypothermia therapy after traumatic brain injury in children". New England Journal of Medicine. 358 (23): 2447–2456. doi:10.1056/NEJMoa0706930. PMID 18525042.

[3] Pryor, Jennifer A.; Prasad, Ammani S. (2008). Physiotherapy for Respiratory and Cardiac Problems: Adults and Paediatrics (به انگلیسی). Elsevier Health Sciences. p. 8. ISBN 0-7020-3974-8.

[NC08-4] ۴٫۰ ^۴٫۱ Axelrod, Yekaterina K.; Diringer, Michael N. (May 2008). "Temperature management in acute neurologic disorders". Neurologic Clinics. 26 (2): 585–603, xi. doi:10.1016/j.ncl.2008.02.005. PMID 18514828.

[CC09-5] ۵٫۰ ^۵٫۱ Laupland, Kevin B. (July 2009). "Fever in the critically ill medical patient". Critical Care Medicine. 37 (7 Suppl): S273–8. doi:10.1097/CCM.0b013e3181aa6117. PMID 19535958.

[6] Grunau, Brian E.; Wiens, Matthew O.; Brubacher, Jeffrey R. (September 2010). "Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review". Canadian Journal of Emergency Medicine. 12 (5): 435–442. doi:10.1017/s1481803500012598. PMID 20880437. Dantrolene may also be associated with improved survival and reduced complications, especially in patients with extreme (≥ 42 °C) or severe (≥ 40 °C) hyperpyrexia

[7] Sharma, Hari Shanker, ed. (2007). Neurobiology of Hyperthermia (1st ed.). Elsevier. pp. 175–177, 485. ISBN 978-0-08-054999-6. Retrieved 19 November 2016. Despite the myriad of complications associated with heat illness, an elevation of core temperature above 41.0 °C (often referred to as fever or hyperpyrexia) is the most widely recognized symptom of this syndrome.

[۱]

[۲]

[۳]

[۴]

[۵]

[۶]

[۷]